宜宾鼻子的假体去还是不去有没有在宜宾做双眼皮好的医院,宜宾割双眼皮年龄,宜宾开眼角整形手术医院,宜宾脸上能做激光脱毛吗,宜宾哪有整双眼皮的地方,宜宾冰点激光无痛脱毛,宜宾割一双双眼皮多少钱

WASHINGTON, Nov. 10 (Xinhua) -- NASA's car-sized Mars rover Curiosity, which will examine one of the most intriguing areas on the Red Planet, is in final preparations for a launch from Florida 's Space Coast at 10:25 a.m. EST (15:25 GMT) on Nov. 25, the U.S. space agency announced on Thursday.Curiosity is about twice as long and more than five times as heavy as any previous Mars rover. Its 10 science instruments include two for ingesting and analyzing samples of powdered rock delivered by the rover's robotic arm. It is now sitting atop an Atlas V rocket awaiting liftoff from Cape Canaveral Air Force Station."Preparations are on track for launching at our first opportunity," said Pete Theisinger, Mars Science Laboratory project manager at NASA's Jet Propulsion Laboratory. "If weather or other factors prevent launching then, we have more opportunities through Dec. 18."Scheduled to land on the Mars in Aug. 2012, the one-ton rover will examine Gale Crater during a nearly two-year prime mission. Curiosity will land near the base of a layered mountain three miles (five kilometers) high inside the crater. The rover will investigate whether environmental conditions ever have been favorable for development of microbial life and preserved evidence of those conditions.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.

BEIJING, Oct. 24 (Xinhuanet) -- The average global land temperature has increased by around one degree Cetigrade since the mid-1950s, American scientists announced last week after reviewing historical temperature records to date.According to media reports, the scientists of the Berkeley Earth project have studied more than a billion temperature records dating back to the 1800s from 15 sources around the world.And the result is in line with the estimate made by major institutions which keep official records on the global climate, including the Nasa's Goddard Institute for Space Studies in the US and the Met Office's Hadley Centre in Britain.Meanwhile, the scientists established an open database for the climate records so that skeptics on climate change can assess climage change on their own.Nevertheless, the finding of the scientists at the University of California, Berkeley did not convince climate change skeptics, according to a New York Times report.Anthony Watts, one prominent US skeptics, claimed the study's "methodology was flawed". He also noted that the finding was submitted to journal Geophysical Research Letters before being peer-reviewed.Richard Muller, a physicist and head of the project, argued that the decision to circulate the papers before publication was part a long-standing academic tradition of sanity-checking results with colleagues.He added, cited by the Guardian, "We will get much more feedback from making these papers public before publication."